India's Sun Pharma Advanced Research slumps 15% after drug fails mid-stage study
** Shares of Sun Pharma Advanced Research SPRC.NS down 15% at 166 rupees, marking worst pct drop since March 2020 ** Co on Tuesday said its partner informed that a drug treating psoriasis did not meet main goal in mid-stage study ** Including session's drop, SPRC down 16% YTD (Reporting by Sethuraman NR in Bengaluru) ((Sethuraman.NR@thomsonreuters.com; (+91 9945291420); Reuters Messaging: nallur.sethuraman.thomsonreuters.com@reuters.net ))
Recent news on Sun Pharma Advanced Research
See all newsAdvisory: Alert incorrectly tagged to Sun Pharma Advanced Research withdrawn
Brief: Sun Pharma Advanced Research Appoints Anil Raghavan As MD And CEO Effective August 11
Brief: Sun Pharma Advanced Research Says Ocuvex Therapeutics Gets Complete Response Letter For PDP-716 NDA
India's Sun Pharma Advanced Research jumps after swinging to Q4 profit
Brief: Sun Pharma Advanced Research March-Quarter Consol Profit 17.61 Billion Rupees